Axalbion SA

Swiss Biotech Association

Not a member

Axalbion is a clinical-stage pharmaceutical company developing TRPM8 agonists for the treatment of chronic cough. Axalbion’s s strategy is to develop its lead compound AX-8 up-to Phase 2b to show clinical proof of concept across a representative patient population.

http://www.axalbion.com/

Location

EPFL Innovation Park, 1015 Lausanne

Get Directions

Facts & figures

Type of organization

Private company
Year of foundation

2017
Number of employees in Switzerland

1-9

Key business

Core competencies

Therapeutics/vaccines (human)

You may also be interested in

InkVivo Technologies AG

InkVivo Technologies combines its patented biomaterial platform with advanced manufacturing technologies to fabricated novel delivery systems that ensure controlled and prolonged release of active ingredients (e.g., small molecules, biologics and micronutrients).
Lugano

Member

Provectis Healthcare AG

Provectis Healthcare AG is a global healthcare company based in Basel and the commercial partner of choice to the innovative biopharma. We advance the innovation through launch, commercialization and brand building in Europe, Middle East and Asia.
4051 Basel

Member

Tenpoint Therapeutics GmbH

Tenpoint is a biotechnology company committed to advancing engineered cell-based therapies and in vivo reprogramming to restore vision for people with degenerative ocular diseases, bringing together the global experts shaping the regenerative ocular medicine revolution.
4051 Basel

Member